期刊文献+

MGMT基因甲基化在胶质瘤化疗及预后中的意义 被引量:9

下载PDF
导出
摘要 化疗是恶性脑肿瘤的重要辅助治疗手段之一,然而其临床效果尚不理想。肿瘤对化疗药物的耐药是影响化疗效果的重要原因。DNA修复蛋白O6-甲基鸟嘌呤DNA甲基转移酶(O6-methylguanine-DNA methyltransferase,MGMT)在肿瘤耐药中的作用比较明确,而MGMT的表达与MGMT基因的甲基化状态密切相关。本文总结有关研究的新进展,对MGMT基因甲基化与胶质瘤化疗及预后的相关性进行综述,为实现恶性胶质瘤预见性、个体化化疗,改善病人预后等提供理论依据。
出处 《中国微侵袭神经外科杂志》 CAS 2007年第10期474-477,共4页 Chinese Journal of Minimally Invasive Neurosurgery
  • 相关文献

参考文献17

  • 1DOLAN M E, SCHILSKY R L. Silence is goldon: gene hypermethylafion and survival in large-cell lymphoma [J]. J Nat Cancer Ins, 2002, 94(1): 6-7.
  • 2PEGG A. Repair of O^6-alkylguainne by alkyltransferases [J]. Mutat Res, 2000, 462(2-3): 83-100.
  • 3BEARZATTO A, SZADKOWSKI M, MACPHERSON P, et al. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents [J]. Cancer Res, 2000, 60(12): 3262-3270,
  • 4HEGI M E, DISERENS A C, GODARD S, et al. Clinical trial substantiates the predictive value of O^6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide [J]. Clin Can cer Res, 2004, 10(6): 1871-1874.
  • 5HEGI M E, DISERENS A C, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma [J]. N Engl J Med, 2005, 352(10): 997-1003.
  • 6HARDEN S V, TOKUMARU Y, WESTRA W H, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage Ⅰ lung cancer patients [J]. Clin Cancer Res, 2003, 9(4): 1370-1375.
  • 7ESTELLER M, HAMILTON S R, BURGER P C, et al. Inactivation of the DNA repair gene O^6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia [J]. Cancer Res, 1999, 59 (4): 793-797.
  • 8PULLING L C, DIVINE K K, KLINGE D M, et al. Promoter hypermethylation of the O^6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression [J]. Cancer Res, 2003, 63(16): 4842-4848.
  • 9NAKAMURA M, WATANABE T, YONEKAWA Y, et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is fi'equently associated with G:C→A:T mutations of the TP53 tumor suppressor gene [J]. Carcinogenesis, 2001, 22(10): 1715-1719.
  • 10TANAKA S, KOBAYASHI I, OKA H, et al. Drug-resistance gene expression and progression of astrocytic tumors [J]. Brain Tumor Pathol, 2001, 18(2): 131-137.

同被引文献155

引证文献9

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部